simonapilolla/iStock via Getty Images
- Harmony Biosciences (NASDAQ:HRMY) says it will begin a phase 3 trial of pitolisant for idiopathic hypersomnia in 1H 2022.
- The company said that the FDA has accepted its IND for the candidate.
- Idiopathic hypersomnia is a rare disease characterized by excessive daytime sleepiness
- Pitolisant is currently marketed as Wakix as a narcoplepsy drug.
- Harmony is one of the companies Goldman Sachs selected last month as a pick due to its growth and high profit margin.